Marker Therapeutics, Inc. (MRKR)
Summary
MARKER THERAPEUTICS (MRKR) Upgraded to Buy: What Does It Mean for the Stock?
MARKER THERAPEUTICS (MRKR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
MARKER THERAPEUTICS, INC. (MRKR) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.21.
MRKR Stock Up Nearly 114% in 3 Months: Here's What You Need to Know
Marker Therapeutics' shares jump 114% in three months as early MT-601 data showed strong responses, advanced into dose expansion, and lifted investor confidence.
Marker Therapeutics, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| KH Kevyn Hill Hilltop National Bank | 73 | $314 | $105.85 | -$208.15 | -66.29% |
| UFP United Financial Planning Group LLC United Financial Planning Group LLC | 250 | $373 | $362.5 | -$10.5 | -2.81% |
Marker Therapeutics, Inc. (MRKR) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Marker Therapeutics, Inc. ever had a stock split?
Marker Therapeutics, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Juan F. Vera CEO | NASDAQ (CM) Exchange | 57055L107 CUSIP |
| US Country | 5 Employees | - Last Dividend | 25 Feb 2014 Last Split | 25 Mar 2014 IPO Date |
Overview
Marker Therapeutics, Inc. stands as a forefront entity in the realm of immuno-oncology, squarely focused on the clinical-stage development and future commercialization of pioneering T cell-based immunotherapies. This innovative endeavor is primarily aimed at addressing hematological malignancies and solid tumor conditions within the United States. Central to its mission, the company leverages its proprietary MultiTAA-specific T cell technology, which significantly diverts from conventional approaches by utilizing non-engineered tumor-specific T cells. These specialized cells are unique for their ability to recognize multiple tumor-associated antigens, thus enabling them to effectively target and annihilate tumor cells. With its headquarters nestled in Houston, Texas, Marker Therapeutics constitutes a beacon of hope in the relentless fight against cancer, showcasing a dynamic commitment to pushing the boundaries of medical science.
Products and Services
-
MultiTAA-specific T cell technology
At the core of its product offering, Marker Therapeutics' MultiTAA-specific T cell technology stands out as a revolutionary approach in the realm of cancer treatment. This advanced technology hinges on the production of non-engineered tumor-specific T cells adept at recognizing and responding to a broad spectrum of tumor-associated antigens. The implication of such a strategy is a more effective targeting and elimination of tumor cells, thereby heralding a new era in immunotherapy.
-
MT-401-OTS
Marker Therapeutics is currently advancing MT-401-OTS, a promising candidate in the treatment of acute myeloid leukemia (AML). Presently in phase 1 clinical trials, MT-401-OTS embodies the company's ambition to deliver targeted therapies that can significantly improve the treatment landscape for patients grappling with this daunting hematological malignancy.
-
MT-601
The company's product pipeline further extends to MT-601, which is under investigation for its potential efficacy in the treatment of lymphoma and pancreatic cancer. In the challenging field of oncology, MT-601 represents a beacon of hope, as it is currently undergoing a phase 1 clinical trial for lymphoma and a combined phase 1/2 clinical trial for pancreatic cancer. The development of MT-601 underscores Marker Therapeutics' commitment to broadening its impact across a variety of cancer types, thereby enhancing treatment modalities for patients worldwide.
